anxiety and glp 1 An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive mental health disorders New research from our team

Guidelines Multiple professional societies, including the ACC, ESC, and ADA, have updated their clinical guideline recommendations to incorporate GLP-1 RAs as a therapy component for patients with T2DM and ASCVD

an early phase 1b study reported that co-administration was feasible and that each components pharmacokinetics were not meaningfully altered by the other, which motivated the phase 3 program [3]

It is necessary to expand extensive chronic clinical trials to evaluate the long-term safety, efficacy, and optimal dosing of polyphenols, examine gene-diet and microbiota-polyphenol interactions to elucidate inter-individual variability, develop innovative delivery systems to improve bioavailability and facilitate clinical translation, and clarify potential drug interactions and safety in vulnerable populations

Regulation of metabolite flux through voltage-gating of VDAC channels

Nusser Z, Lujan R, Laube G, Roberts JD, Molnar E, Somogyi P (1998)